BioVaxys Technology Corp.
BVAXF
$0.0388
$0.003810.86%
| Weiss Ratings | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.16 | |||
| Price History | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.60% | |||
| 30-Day Total Return | -16.92% | |||
| 60-Day Total Return | 10.54% | |||
| 90-Day Total Return | -28.41% | |||
| Year to Date Total Return | -16.92% | |||
| 1-Year Total Return | -27.75% | |||
| 2-Year Total Return | -39.38% | |||
| 3-Year Total Return | -63.05% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -40.23% | |||
| 52-Week Low % Change | 33.97% | |||
| Price | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.07 | |||
| 52-Week Low Price | $0.03 | |||
| 52-Week Low Price (Date) | Oct 16, 2024 | |||
| 52-Week High Price (Date) | Apr 02, 2024 | |||
| Valuation | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.97M | |||
| Enterprise Value | 9.69M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -75.67% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -55.50 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.04 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -5.35 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 220.08M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646-452-7054 | |||
| Address | 146 Thirtieth Street Etobicoke, ON M8W 3D4 | |||
| Website | biovaxys.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -80.41% | |||
| Return on Equity | -- | |||
| Income Statement | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -1.81M | |||
| Net Income (TTM) | -3.58M | |||
| Net Income Avl. to Common (TTM) | -3.58M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 59.08% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | 72.92% | |||
| Balance Sheet | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 355.30K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 741.30K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -180.40K | |||
| Current Ratio (Q) | 0.385 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 1.74M | |||
| Total Current Liabilities (Q) | 1.92M | |||
| Total Debt (Q) | 58.80K | |||
| Total Liabilities (Q) | 1.92M | |||
| Total Common Equity (Q) | -180.40K | |||
| Cash Flow | BVAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -778.50K | |||
| Cash from Financing (TTM) | 1.76M | |||
| Net Change in Cash (TTM) | 362.80K | |||
| Levered Free Cash Flow (TTM) | 1.07M | |||
| Cash from Operations (TTM) | -622.70K | |||
